Coherus Biosciences Inc Live Stock Price Today, Share Analysis and Chart

Name: Coherus Biosciences Inc: Is Infosys Ltd. worth buying?
Item: Coherus Biosciences Inc
Rating: 2.660930625
Author: Trendlyne DVM scores

Turnaround Potential

about

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and o...

2.16 -0.17 (-7.30%)

New 52W High in past week

1.9M

XNAS Volume

XNAS 30 Jan, 2026 4:30 PM (EST)

Medium Financial Strength

38.9 / 100

Affordable Valuation

56.7 / 100

Technically Bullish

78.4 / 100

Turnaround Potential These stocks have average financials with good valuations and momentum, indicating turnaround potential View Similar Embed DVM

1Yr Price target upside is 212%

4 analysts

Coherus Biosciences Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Coherus Biosciences Inc Live Stock Price Today, Share Analysis and Chart

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and o...

New 52W High in past week

SWOT Analysis

Coherus Biosciences Inc Live Price Chart